Please assess the completion status of the following clinical trial:

Trial Title: Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Ages 18-75 years inclusive.~* Ability to comprehend the investigational nature of the study and provide informed consent.~* Thrombocytopenia (due to congenital causes, bone marrow failure, hematologic malignancies, and treatment related), defined as \<10k/uL without bleeding or \<30K/uL with evidence of life threatening bleeding (intracranial hemorrhage, GI bleeding, pulmonary hemorrhage, uncontrolled epistaxis, hematuria).~* Diagnosed with immune platelet refractoriness, characterized by all of the following:~  * Lack of adequate post-transfusion platelet count increment, defined by, CCI \<7500/ul at 10-60 min, and CCI \<5000/ul at 18-24 hrs (in those who had a CCI at 10-60 min greater than or equal to 5000/microl)after at least 2 consecutive transfusions.~ * Presence of anti-HLA class A and/or B antibody.~EXCLUSION CRITERIA:~* Active meningococcal infection.~* Severe psychiatric illness. Mental deficiency sufficiently severe as to make making informed consent impossible.~* Positive pregnancy test for women of childbearing age within 1 week.~* HIV positive test within 3 months~* Paroxysmal Nocturnal Hemoglobinuria (PNH) disease with evidence of intravascular hemolysis.~* Presence ITP/autoimmune thrombocytopenia~* Immune platelet refractoriness responsive to treatment with IVIG~RE-ENROLLMENT CRITERIA:~* Meet response criteria to the initial treatment or second treatment~* Meets all initial inclusion/exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): 1200 mg IV infusion over 30-40 min

Based on this trial design, predict the completion outcome and termination type (if applicable).